PRKCD and colonic neoplasm: Recent data from our group demonstrated that 7α-acetoxy-6β-benzoyloxy-12-O-benzoylroyleanone (Roy-Bz) is the first PKCδ-selective activator with promising antitumor properties in colon cancer [16].